Unigestion Holding SA Has $5 Million Position in Zoetis Inc (ZTS)

Share on StockTwits

Unigestion Holding SA lessened its holdings in Zoetis Inc (NYSE:ZTS) by 43.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 54,590 shares of the company’s stock after selling 41,198 shares during the period. Unigestion Holding SA’s holdings in Zoetis were worth $4,999,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Polen Capital Management LLC increased its stake in Zoetis by 3.9% in the 2nd quarter. Polen Capital Management LLC now owns 9,295,080 shares of the company’s stock valued at $791,848,000 after buying an additional 351,447 shares during the last quarter. Massachusetts Financial Services Co. MA increased its stake in Zoetis by 1.6% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 7,692,247 shares of the company’s stock valued at $704,302,000 after buying an additional 119,154 shares during the last quarter. Wells Fargo & Company MN increased its stake in Zoetis by 9.1% in the 2nd quarter. Wells Fargo & Company MN now owns 6,375,146 shares of the company’s stock valued at $543,099,000 after buying an additional 529,666 shares during the last quarter. Janus Henderson Group PLC increased its stake in Zoetis by 22.3% in the 2nd quarter. Janus Henderson Group PLC now owns 5,410,040 shares of the company’s stock valued at $460,890,000 after buying an additional 985,586 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its stake in Zoetis by 8.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 5,262,461 shares of the company’s stock valued at $448,309,000 after buying an additional 422,856 shares during the last quarter. Institutional investors own 89.68% of the company’s stock.

In other news, insider Catherine A. Knupp sold 46,816 shares of the stock in a transaction that occurred on Wednesday, August 15th. The shares were sold at an average price of $90.84, for a total transaction of $4,252,765.44. Following the completion of the transaction, the insider now directly owns 81,640 shares of the company’s stock, valued at approximately $7,416,177.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Juan Ramon Alaix sold 150,306 shares of the stock in a transaction that occurred on Thursday, November 8th. The shares were sold at an average price of $94.96, for a total transaction of $14,273,057.76. Following the transaction, the chief executive officer now directly owns 246,319 shares of the company’s stock, valued at $23,390,452.24. The disclosure for this sale can be found here. Insiders have sold a total of 350,507 shares of company stock valued at $32,579,830 over the last three months. Insiders own 0.35% of the company’s stock.

Several equities research analysts have commented on ZTS shares. Stifel Nicolaus increased their price objective on shares of Zoetis from $86.00 to $95.00 and gave the company a “buy” rating in a research note on Friday, August 3rd. Morgan Stanley increased their price objective on shares of Zoetis from $87.00 to $92.00 and gave the company a “hold” rating in a research note on Friday, August 3rd. Cantor Fitzgerald set a $98.00 price objective on shares of Zoetis and gave the company a “buy” rating in a research note on Friday, July 27th. JPMorgan Chase & Co. increased their price objective on shares of Zoetis from $100.00 to $101.00 and gave the company an “overweight” rating in a research note on Friday, November 2nd. Finally, Jefferies Financial Group set a $96.00 price objective on shares of Zoetis and gave the company a “buy” rating in a research note on Friday, July 13th. Seven research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $93.19.

Zoetis stock opened at $95.27 on Friday. Zoetis Inc has a twelve month low of $68.56 and a twelve month high of $96.57. The company has a market cap of $45.73 billion, a PE ratio of 31.31, a P/E/G ratio of 1.87 and a beta of 0.97. The company has a quick ratio of 2.63, a current ratio of 4.06 and a debt-to-equity ratio of 3.04.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, November 1st. The company reported $0.83 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.77 by $0.06. Zoetis had a net margin of 20.35% and a return on equity of 75.51%. The firm had revenue of $1.48 billion during the quarter, compared to the consensus estimate of $1.46 billion. During the same period in the prior year, the firm earned $0.65 EPS. The company’s revenue was up 9.9% compared to the same quarter last year. On average, equities analysts expect that Zoetis Inc will post 3.11 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Monday, December 3rd. Stockholders of record on Tuesday, November 20th will be given a dividend of $0.126 per share. This represents a $0.50 dividend on an annualized basis and a dividend yield of 0.53%. The ex-dividend date of this dividend is Monday, November 19th. Zoetis’s dividend payout ratio is currently 20.83%.

TRADEMARK VIOLATION WARNING: “Unigestion Holding SA Has $5 Million Position in Zoetis Inc (ZTS)” was originally published by Week Herald and is the property of of Week Herald. If you are reading this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this piece of content can be viewed at https://weekherald.com/2018/11/10/unigestion-holding-sa-has-5-million-position-in-zoetis-inc-zts.html.

Zoetis Company Profile

Zoetis, Inc discovers, develops and manufactures a portfolio of animal health medicines and vaccines. Its products are complemented by diagnostic products, genetic tests, bio devices and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal. The firm provides its services though five categories namely, anti-invectives, vaccines, parasitic ides, medicated feed additives, and other pharmaceuticals.

Featured Story: Is the Dow Jones Industrial Average (DJIA) still relevant?

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply